Effect of Long Term Trimetazidine Treatment on Final Myocardial Fibrosis for ST Eleviation Myocardial Infarction

Trimetazidine is a agent promoting glucose utilization by limiting fatty-acid oxidation.Trimetazidine could improve cardiac function in patients with ischemic heart disease. We aimed to explore effect of Trimetazidine on final myocardial fibrosis for patients with ST-elevation myocardial infarction (STEMI) in real world clinical practice. In this observational study, we investigated the effect of long-term treatment with trimetazidine on the final extent of myocardial fibrosis measured by cardiac magnetic resonance 6 months after infarction in real world clinical practice.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

ST Elevation Myocardial Infarction (STEMI) Cardiovascular Diseases Heart Diseases Infarction Ischemia Myocardial Infarction Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms ST Elevation Myocardial Infarction Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Chinese PLA general hospital

Beijing, Haidian, 100853, China

About this study

This study is an prospective observational real-world clinical research. We evaluated the effect of long term trimetazidine treatment after the primary percutaneous coronary intervention (PCI), the myocardial infarction size in STEMI patients could be further reduced by metabolic regulation therapy. This study contributes to the development of standardized treatment procedure for STEMI patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosed STEMI patients within one day after reperfusion threapy; Have performed the primary PCI procedure; Sign the informed consent form for this cohort study

Exclusion criteria

Mechanical complications; Cardiogenic shock; Malignant tumors, severe infection, hepatic or renal failure, respiratory failure, or other short-term progressive diseases

Treatment and study plan

Primary outcomes

myocardial fibrosis measured by cardiac magnetic resonance imaging

Time frame: 6 months after infarction

Delayed enhancement of cardiac magnetic resonance imaging showed the myocardial fibrosis after infarction

Sponsors and collaborators

Lead sponsor

Chinese PLA General Hospital

Other

Registry information

Official study title

Effect of Long Term Trimetazidine Treatment on Myocardial Final Fibrosis for Acute Myocardial Infarction

Acronym: Easy

Important dates

Study start: 2020
Primary completion: 2024
Study completion: 2024
First posted: Jan 8, 2026
Registry last updated: Jan 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed